Medical Devices

FirmTech is taking its AI-powered sexual wellness wearables worldwide, betting on data to revolutionize men's health. But can it navigate global privacy hurdles?

With a new board member and strategic investment, Kandu, Inc. is set to scale its brain-computer interface technology for stroke recovery.

Carlsmed's AI-driven aprevo® platform shows massive surgeon adoption and market growth, signaling a new era of personalized, cost-effective spine care.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

ConcertAI and Foundation Medicine unite to create a huge dataset of 500k patients, using AI to accelerate the hunt for new life-saving cancer drugs.

A major new partnership is racing to deploy predictive tech, from blood tests to eye scans, to prevent millions of stillbirths in years, not decades.

FDA clears a novel two-part immunotherapy that paints solid tumors with a synthetic target, unleashing a powerful CAR T-cell attack in a new clinical trial.

AbbVie inks a massive deal for a novel bispecific antibody, aiming to combine it with ADCs and enter the high-stakes race for solid tumor therapies.

Backed by Purolator, a massive network expansion by Williams Pharmalogistics aims to reshape Canada's temperature-controlled medical delivery landscape.

TriSalus Life Sciences reports record 53% annual revenue growth, but a closer look reveals a complex financial picture for the oncology innovator.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

The pediatric device firm posted 15% growth to $236.1M in 2025, issuing strong 2026 guidance fueled by its specialty bracing and European expansion.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Amidst a strategic push for profitability, CytoSorbents advances its DrugSorb-ATR device, aiming to revolutionize safety in cardiac surgery.

With new funding, Nanochon is advancing its 3D-printed Chondrograft™ implant, offering hope for faster recovery to patients with chronic knee damage.

A federal court blocked Edwards Lifesciences' key acquisition, citing monopoly fears, yet the company's financial outlook surprisingly improves.

Recent findings of bacteria and heavy metals in baby formula have parents worried and legal experts demanding greater manufacturer accountability.